Drugs / LM103 TILs
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07444437 | Feb 2026 → Dec 2027 expected | non-small cell lung carcinoma | Suzhou BlueHorse Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07310784 | Dec 2025 → Dec 2027 expected | melanoma | Suzhou BlueHorse Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LM103 TILs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07444437 ↗ |
| Modality | Cell therapy | “Extract, culture and expand tumor-infiltrating lymphocytes from resected tumor tissues in vitro” NCT07310784 ↗ |
| Route | Other | “the subjects received LM103 infusion” NCT07310784 ↗ |